NIOX GroupCSSPF 77 Current Ratio is 3.81 as of Dec. 2025, which is 38% above its 10-year median of 2.76. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 854 Medical Devices & Instruments companies, NIOX Group ranks better than 67.92% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. NIOX Group's current ratio for the quarter that ended in Dec. 2025 was 3.81.
NIOX Group has a current ratio of 3.81. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for NIOX Group's Current Ratio or its related term are showing as below:
CSSPF'
s Current Ratio Range Over the Past 10 Years
Min: 0.43 Med: 2.76 Max: 6.44
Current: 3.81
During the past 13 years, NIOX Group's highest Current Ratio was 6.44. The lowest was 0.43. And the median was 2.76.
CSSPF's Current Ratio is ranked better than 67.92% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs CSSPF: 3.81
NIOX Group (OTCPK:CSSPF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
NIOX Group Current Ratio Related Terms
NIOX Group Current Ratio Historical Data
* Premium members only.
The historical data trend for NIOX Group's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Current Ratio distribution charts can be found below:
* The bar in red indicates where NIOX Group's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Current Ratio of 3.81 as of Dec. 2025. This is 38% above median its historical median of 2.76. Over the past decade, NIOX Group's Current Ratio has ranged from 0.43 to 6.44. According to the industry distribution chart, NIOX Group ranks #274 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 32.1%.
Is NIOX Group's Current Ratio too high?
NIOX Group's current Current Ratio of 3.81 is 38% above median its 10-year median of 2.76. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 6.44. The Medical Devices & Instruments industry median Current Ratio is 2.49. NIOX Group's value of 3.81 is 53% above this industry median. Based on the distribution chart, NIOX Group ranks #274 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #274 out of 854 companies for Current Ratio. This puts NIOX Group in the upper half of its industry. The industry median Current Ratio is 2.49. NIOX Group's value of 3.81 is 53% above this benchmark. Historically, NIOX Group's own Current Ratio has ranged from 0.43 to 6.44 over the past decade. While the company's 10-year median is 2.76 vs. the industry median of 2.49, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Current Ratio of 3.81 is 53% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Current Ratio is 3.81, which is 38% above median its own 10-year median of 2.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current Current Ratio is 3.81, which is 38% above median its 10-year median of 2.76 and 53% above the Medical Devices & Instruments industry median of 2.49. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Current Ratio is 3.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Current Ratio: 3.81 (38% above median its 10-year median of 2.76)
GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
Industry Position: 53% above the Medical Devices & Instruments median (#274 of 854)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
